Annual report pursuant to Section 13 and 15(d)

Licensing and Other Arrangements - Rezolute - Additional Information (Details)

v3.10.0.1
Licensing and Other Arrangements - Rezolute - Additional Information (Details)
 3 Months Ended 12 Months Ended 18 Months Ended
Mar. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
Apr. 03, 2018
USD ($)
Obligation
shares
Mar. 30, 2018
USD ($)
shares
Dec. 06, 2017
USD ($)
shares
Mar. 31, 2018
USD ($)
shares
Dec. 31, 2018
USD ($)
Jun. 01, 2019
USD ($)
Dec. 31, 2017
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Gross proceeds from debt financing activity             $ 7,500,000    
Rezolute [Member] | Initial Closing [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Common stock value receivable       $ 5,000,000          
Rezolute [Member] | Qualified Financing [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Common stock value receivable       7,000,000          
Rezolute [Member] | 2019 Closing [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Common stock value receivable       $ 7,000,000          
Rezolute [Member] | License Agreement [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Future milestone payments, maximum         $ 232,000,000        
Eligible to receive in cash         6,000,000        
Eligible to receive common stock, financing activities         $ 12,000,000        
Number of shares of common stock held for future issuance | shares         5,000,000        
Common stock purchase agreement description             Under the common stock purchase agreement, Rezolute granted the Company the right and option to sell the greater of (i) 5,000,000 shares of common stock or (ii) one third of the aggregate shares held by the Company upon failure by Rezolute to list its shares of its common stock on the Nasdaq Stock Market or a similar national exchange on or prior to December 31, 2018.    
Percentage of aggregate shares held for future issuance         33.33%        
Agreement termination notice period         90 days        
Reimbursable technology transfer expenses received             $ 300,000    
Contract assets                 $ 0
Contract liabilities             $ 0   0
Capitalized contract costs                 $ 0
Rezolute [Member] | License Agreement [Member] | Forecast [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Future milestone payments, maximum               $ 237,000,000  
Upfront option fee               $ 1,000,000  
Gross proceeds from qualified financing   $ 20,000,000              
Additional common stock receive for qualified financing   $ 7,000,000              
Common stock, trading period   10 days              
Eligible to receive, in order to maintain license agreement $ 15,000,000                
Rezolute [Member] | Amended Common Stock Purchase Agreement [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Common stock received | shares     8,023,758            
Cash received     $ 500,000            
Gross proceeds from debt financing activity     4,000,000            
Reimbursable technology transfer expenses received     $ 300,000            
Rezolute [Member] | Amended Common Stock Purchase Agreement [Member] | Initial Closing [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Common stock shares receivable | shares       7,000,000          
Rezolute [Member] | Amended Common Stock Purchase Agreement [Member] | Qualified Financing [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Common stock value receivable       $ 8,500,000          
Rezolute [Member] | Amended Common Stock Purchase Agreement [Member] | 2019 Closing [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Common stock value receivable       $ 8,500,000          
Rezolute [Member] | Common Stock Purchase Agreement [Member] | Interim Financing Closing [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Common stock received | shares           69,252,000      
Cash received           $ 50,000      
Contract revenue           $ 0      
Rezolute [Member] | Amended License Agreement and Amended Common Stock Purchase Agreement [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Common stock received | shares     8,093,010            
Cash received     $ 500,000            
Reimbursable technology transfer expenses received     $ 300,000            
Number of performance obligations | Obligation     1            
Upfront consideration to incremental discount for future payment     $ 0            
Remaining performance obligations     0            
License agreement transaction price     1,800,000            
Value of common stock received     1,000,000            
Rezolute [Member] | Amended License Agreement and Amended Common Stock Purchase Agreement [Member] | Licenses and Related Materials, Product Data/Filing, Process and Know-how [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Recognized the entire transaction price as revenue upon completion of delivery     $ 1,800,000